Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Systemic Inflammatory Response Syndrome Treatment Market size was over USD 13.63 billion in 2024 and is poised to exceed USD 29.43 billion by 2037, growing at over 6.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of systemic inflammatory response syndrome treatment is evaluated at USD 14.34 billion.
Increasing incidences of systemic inflammatory response syndrome disease due to lifestyle changes, raising awareness about the disease, and the availability of treatments is expected to fuel this market's progress. The growth of the market can also be attributed to the rising prevalence of SIRS disease amongst individuals on a global level.
Systemic Inflammatory Response Syndrome Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing incidence of systemic inflammatory response syndrome due to lifestyle changes
- Increasing awareness about the disease, and the availability of treatments
Challenges
- High cost of treatment
- Delay in diagnosis and lack of awareness
Systemic Inflammatory Response Syndrome Treatment Market: Key Insights
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6.1% |
|
Base Year Market Size (2023) |
USD 12.85 billion |
|
Forecast Year Market Size (2036) |
USD 27.75 billion |
|
Regional Scope |
|
Systemic Inflammatory Response Syndrome Treatment Segmentation
On the basis of indication type, the systemic inflammatory response syndrome treatment market is segmented into meningitis, urinary tract infection (UTI), pneumonia, hemorrhage, autoimmune diseases, and others. Out of which, revenue from the treatment of urinary tract infection holds the highest share as dehydration, high consumption of birth control pills, menopause, and frequent involvement in sexual activities are leading causes of UTI. Females are more prone to UTI as they have a shorter urethra than males as a result, which shortens the distance for bacteria to reach the bladder.
On the basis of end-users, the market is segmented into hospital & ambulatory surgical centers, specialty clinics, and others. Specialty clinics segment hold the highest share of the systemic inflammatory response syndrome treatment market as a considerable portion of the population with disease on a global level tend to choose healthcare facilities specializing in specific treatment.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSystemic Inflammatory Response Syndrome Treatment Industry - Regional Synopsis
Geographically, the systemic inflammatory response syndrome treatment market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa region. The market in the Asia Pacific industry is likely to dominate majority revenue share by 2037, owing to increasing awareness about the disease and the need to develop innovative inflammatory disease treatment solutions in the region.
In 2021, the market in North America is evaluated to occupy the largest share in terms of revenue followed by Europe.
Companies Dominating the Systemic Inflammatory Response Syndrome Treatment Landscape
- RegeneRx Biopharmaceuticals, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Endacea, Inc.
- Adrenomed AG
- GlaxoSmithKline plc
- Asahi Kasei Corporation
- Cardinal Health
- Smith & Nephew plc
- ConvaTec, Inc.
- AstraZeneca
- Orion Corporation
- CHIESI Farmaceutici S.p.A.
- Mylan N.V.
In the News
Author Credits: Radhika Pawar
- Report ID: 3013
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
